HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Diederichs, C. G. Articles by Reske, S. N. Search for Related Content PubMed PubMed Citation Articles by Diederichs, C. G. Articles by Reske, S. N.

FDG PET: Elevated Plasma Glucose Reduces Both Uptake and Detection Rate of Pancreatic Malignancies

Departments of Nuclear Medicine and Surgery, University of Ulm, Ulm, Germany

Correspondence: For correspondence or reprints contact: Professor Sven Norbert Reske, MD, Abteilung Nuklearmedizin, Klinikum der Universität Ulm, Robert-Koch-Str. 8, D-89070 Ulm, Germany.

ABSTRACT

The aim of the study was to evaluate the effects of elevated plasma glucose levels on tumor detection. Methods: One-hundred and seventy-one fasted patients (100 malignant pancreatic tumors, 46 chronic pancreatitis and 25 patients with other benign pancreatic lesions) were studied with ¹⁸F-fluorodeoxyglucose (FDG) PET before planned resective pancreatic surgery. Nineteen of 171 patients had elevated plasma glucose levels above 130 mg/dl, and 24 of 171 had diabetes mellitus. Standard uptake values (SUVs) with and without glucose correction, tumor-to-muscle ratios and tumor-to-liver ratioswere measured of the pancreatic lesion respective of the area with the highest uptake within the pancreas. The original qualitative PET reports concerning the dignity of the pancreatic lesion were translated into a five-point malignancy scale. Tumor detection rates and SUVs were compared according to plasma glucose levels above and below 130 mg/dl, the presence of diabetes and by using receiver operating characteristic (ROC) analysis. Results: The detection rates (and mean SUVs) for pancreatic malignancies were 86% and 42% (4.2 and 2.3) if fasted plasma glucose levels were below and above 130 mg/dl, respectively. The sensitivities (and mean SUVs of malignant tumors) were 83% and 69% (3.3 and 2.5) for patients without and with known diabetes. Areas under ROC curves were nearly equal for glucose corrected SUV and visual qualitative results (0.86 and 0.85), followed by uncorrected SUV (0.83), tumor-to-liver ratios (0.80 ) and tumor-to-muscle ratios (0.79). SUVs for chronic pancreatitis, muscle and liver had a tendency to increase with elevated plasma glucose levels. Conclusion: Negative PET results of patients with elevated plasma glucose should be interpreted with caution.

Key Words: fluorine-18-fluorodeoxyglucose • plasma glucose • pancreatic tumors

This article has been cited by other articles:

				K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al. In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444. [Abstract] [Full Text] [PDF]

				Z. Keidar, A. Engel, A. Hoffman, O. Israel, and S. Nitecki Prosthetic Vascular Graft Infection: The Role of 18F-FDG PET/CT J. Nucl. Med., August 1, 2007; 48(8): 1230 - 1236. [Abstract] [Full Text] [PDF]

				J. Meller, C.-O. Sahlmann, and A. K. Scheel 18F-FDG PET and PET/CT in Fever of Unknown Origin J. Nucl. Med., January 1, 2007; 48(1): 35 - 45. [Abstract] [Full Text] [PDF]

				W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]

				Z. Keidar, D. Militianu, E. Melamed, R. Bar-Shalom, and O. Israel The Diabetic Foot: Initial Experience with 18F-FDG PET/CT J. Nucl. Med., March 1, 2005; 46(3): 444 - 449. [Abstract] [Full Text] [PDF]

				L. Boucher, S. Rodrigue, R. Lecomte, and F. Benard Respiratory Gating for 3-Dimensional PET of the Thorax: Feasibility and Initial Results J. Nucl. Med., February 1, 2004; 45(2): 214 - 219. [Abstract] [Full Text] [PDF]

				B B Chin and R L Wahl 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies Gut, June 1, 2003; 52(90004): iv23 - 29. [Abstract] [Full Text] [PDF]

				M. F. Kalady, B. M. Clary, L. A. Clark, M. Gottfried, E. M. Rohren, R. E. Coleman, T. N. Pappas, and D. S. Tyler Clinical Utility of Positron Emission Tomography in the Diagnosis and Management of Periampullary Neoplasms Ann. Surg. Oncol., October 1, 2002; 9(8): 799 - 806. [Abstract] [Full Text] [PDF]

				A G Pitman, R J Hicks, D S Binns, R E Ware, V Kalff, A F McKenzie, D L Ball, and M P MacManus Performance of sodium iodide based 18F-fluorodeoxyglucose positron emission tomography in the characterization of indeterminate pulmonary nodules or masses Br. J. Radiol., February 1, 2002; 75(890): 114 - 121. [Abstract] [Full Text] [PDF]

				A. C. Buck, H. H. Schirrmeister, C.-A. Guhlmann, C. G. Diederichs, C. Shen, I. Buchmann, J. Kotzerke, D. Birk, T. Mattfeldt, and S. N. Reske Ki-67 Immunostaining in Pancreatic Cancer and Chronic Active Pancreatitis: Does In Vivo FDG Uptake Correlate with Proliferative Activity? J. Nucl. Med., May 1, 2001; 42(5): 721 - 725. [Abstract] [Full Text]

				I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]